Volume 117, Issue 3 , Pages 563-570, March 2006
Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down
Background
Asthma control is the goal of treatment, but little data exist to support treatment strategies for stepping down treatment once control has been achieved.
Objective
We assessed whether either the long-acting β2-agonist or corticosteroid could be reduced without loss of asthma control once control had been attained with fluticasone propionate/salmeterol (FSC).
Methods
After 12 weeks of open-label treatment with FSC 250/50 μg twice daily, patients whose asthma was well controlled were randomized to FSC 100/50 μg twice daily or fluticasone propionate (FP) 250 μg twice daily. for 12 weeks. The primary endpoint was mean morning peak expiratory flow over the randomized study period. Secondary endpoints included symptom scores, rescue albuterol use, and asthma control.
Results
During open-label treatment, improvements from baseline were seen, and 435 of 641 patients (68%) achieved well controlled status during each of the last 4 weeks of this period. A total of 246 patients received FSC 100/50 μg twice daily and 238 FP 250 μg twice daily. The adjusted mean change in morning peak expiratory flow from the end of open-label treatment was −0.3 L/min for FSC and −13.2 L/min for FP (treatment difference, 12.9 L/min; 95% CI, 8.1-17.6; P < .001). Secondary efficacy endpoints also showed FSC 100/50 μg twice daily to be more effective than FP 250 μg twice daily alone. The majority of patients remained well controlled, but the proportion was higher with FSC.
Conclusion
In patients achieving asthma control with FSC 250/50 μg twice daily, stepping treatment down to a lower dose of FSC 100/50 μg twice daily is more effective than switching to an inhaled corticosteroid alone.
Key words: Asthma, fluticasone propionate, fluticasone propionate/salmeterol, maintenance, control, step-down
Abbreviations used: FP, Fluticasone propionate, FSC, Fluticasone propionate/salmeterol combination product, GOAL, Gaining Optimal Asthma ControL, ITT, Intent-to-treat, OR, Odds ratio, PEF, Peak expiratory flow, PP, Per protocol
Supported by GlaxoSmithKline R & D Limited.Disclosure of potential conflict of interest: L. Jaques and M. Duggan are employed with and own stock in GlaxoSmithKline. E. D. Bateman has consultant arrangements with Boehringer Ingelheim, Pfizer, Aventis, Hoffmann le Roche, and GlaxoSmithKline; is on the speakers' bureau for AstraZeneca, Altana, Boehringer Ingelheim, GlaxoSmithKline, and Merck; and is on the advisory board for AstraZeneca, Altana, Boehringer Ingelheim, GlaxoSmithKline, and Hoffmann le Roche. C. Goldfrad is employed by GlaxoSmithKline. T. Atienza is on the speakers' bureau of GlaxoSmithKline Philippines Inc. T. Mihaescu has consultant arrangements with GlaxoSmithKline, AstraZeneca, and Merck Sharp Dohme and has received research support from GlaxoSmithKline.
PII: S0091-6749(05)02594-7
doi:10.1016/j.jaci.2005.11.036
© 2006 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
Volume 117, Issue 3 , Pages 563-570, March 2006
